Oxycontin and Braftovi drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Oxycontin (oxycodone hydrochloride) and Braftovi (encorafenib). Common drug interactions include pyrexia among females and vomiting among males.

The phase IV clinical study analyzes what interactions people have when they take Oxycontin and Braftovi. It is created by eHealthMe based on reports of 31 people who take the same drugs from the FDA, and is updated regularly.

What is Oxycontin?

Oxycontin has active ingredients of oxycodone hydrochloride. It is often used in pain. eHealthMe is studying from 212,533 Oxycontin users. Check the latest studies of Oxycontin.

What is Braftovi?

Braftovi has active ingredients of encorafenib. eHealthMe is studying from 7,609 Braftovi users. Check the latest studies of Braftovi.

On Jul, 16, 2026

31 people who take Oxycontin and Braftovi together, and have interactions are studied.

Oxycontin and Braftovi drug interactions.

What are the common drug interactions of Oxycontin and Braftovi, by gender? *:

female:

Pyrexia (fever)
Biliary obstruction
Cholangitis (infection of the bile duct)
Infusion related reaction
Liver abscess (pus in liver)
Decreased appetite
Dehydration (dryness resulting from the removal of water)
Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)
Hepatic encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure)
Neoplasm progression (growth of tumour)

male:

Vomiting
Death
Paronychia (infection in the tissues adjacent to a nail on a finger or toe)
Disease progression
Neoplasm progression (growth of tumour)
Peripheral swelling
Constipation
Dermatitis acneiform (dermatoses including acne vulgaris, rosacea, folliculitis, and perioral dermatitis)
Diarrhoea
Dry skin

What are the common drug interactions of Oxycontin and Braftovi, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Neoplasm progression (growth of tumour)
Peripheral swelling
Vomiting
Death
Disease progression

40-49:

n/a

50-59:

Death

60+:

Pyrexia (fever)
Biliary obstruction
Neoplasm progression (growth of tumour)
Death
Dermatitis acneiform (dermatoses including acne vulgaris, rosacea, folliculitis, and perioral dermatitis)
Diarrhoea
Dry skin
Malaise (a feeling of general discomfort or uneasiness)
Nausea (feeling of having an urge to vomit)
Paronychia (infection in the tissues adjacent to a nail on a finger or toe)

What are the existing conditions these people have? *

Malignant Melanoma (skin cancer rises from melancytes): 7 people, 22.58%
Colon Cancer: 5 people, 16.13%
Neoplasm Malignant (cancer tumour): 4 people, 12.90%
Rectal Cancer (cancer of rectum): 3 people, 9.68%
Cholangiocarcinoma (a cancer that forms glands or secretes significant amounts of mucins): 3 people, 9.68%
Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 2 people, 6.45%
Constipation: 2 people, 6.45%

* Approximation only. Some reports may have incomplete information.

Do you take Oxycontin and Braftovi?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously